Clinical Efficacy Analysis of Botulinum Toxin Type A Combined with Superficial Radiotherapy after Chest Keloid...

There are many treatments for keloid. In recent years, botulinum toxin type A(BTX-A)has been proposed to treat keloid. The purpose of our study was to observe the clinical effect of BTX-A combined with superficial radiotherapy after chest keloid surgery.

60 patients with medium and large chest keloid treated from October 2021 to October 2023 were selected and randomly divided into group A and group B, with 30 cases in each group. Keloid resection was performed in both groups first, group A was treated with BTX-A combined with superficial radiotherapy, group B only received early superficial radiotherapy after surgery, and the therapeutic effect of the two groups was compared.

After 6 months follow-up observation, the total effective rate and satisfaction of group A were higher than those of group B, and the Vancouver scar scale(VSS) score of group A was lower than that of group B, the difference was statistically significant (P < 0.05).

We concluded that immediate injection of BTX-A combined with superficial radiotherapy after chest keloid surgery was superior to simple superficial radiotherapy after surgery, with higher patient satisfaction and lower recurrence rate, which was worthy of clinical application.

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .